PEPCID AC Maximum Strength is a Oral Tablet, Film Coated in the Human Otc Drug category. It is labeled and distributed by Johnson & Johnson Consumer Inc., Mcneil Consumer Healthcare Division. The primary component is Famotidine.
Product ID | 16837-855_03eabe8f-7603-4cc8-93cf-a3b5b795ba51 |
NDC | 16837-855 |
Product Type | Human Otc Drug |
Proprietary Name | PEPCID AC Maximum Strength |
Generic Name | Famotidine |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA / NDA |
Application Number | NDA020325 |
Labeler Name | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division |
Substance Name | FAMOTIDINE |
Active Ingredient Strength | 20 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2003-09-01 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing End Date | 2010-12-07 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing End Date | 2015-04-27 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Billing Unit | EA |
Marketing Start Date | 2003-09-01 |
Marketing End Date | 2014-03-31 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing End Date | 2010-12-07 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Billing Unit | EA |
Marketing Start Date | 2014-08-22 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2015-04-27 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing End Date | 2015-12-15 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Billing Unit | EA |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing End Date | 2010-12-07 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Billing Unit | EA |
Marketing Start Date | 2003-09-01 |
Marketing Category | NDA |
Application Number | NDA020325 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2003-09-01 |
Marketing End Date | 2015-12-15 |
Ingredient | Strength |
---|---|
FAMOTIDINE | 20 mg/1 |
SPL SET ID: | 2854047f-c5c4-43c3-8ef2-5c0a84a307f2 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
16837-855 | PEPCID AC Maximum Strength | PEPCID AC Maximum Strength |
0363-0141 | Acid Controller | Famotidine |
0363-0701 | Acid Controller | Famotidine |
0363-1203 | acid controller | famotidine |
0113-7141 | basic care acid reducer | Famotidine |
0113-7194 | Basic Care famotidine | Famotidine |
0093-2748 | Famotidine | Famotidine |
0172-5728 | Famotidine | Famotidine |
0172-5729 | Famotidine | Famotidine |
0338-5197 | Famotidine | Famotidine |
0363-0036 | Famotidine | Famotidine |
0363-1899 | Famotidine | Famotidine |
0113-0141 | good sense acid reducer | Famotidine |
0113-0194 | Good Sense Acid Reducer | Famotidine |
0187-4420 | Pepcid | famotidine |
0187-4440 | Pepcid | famotidine |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
PEPCID AC 74565086 1984651 Live/Registered |
JOHNSON & JOHNSON 1994-08-24 |
PEPCID AC 74242973 1812672 Dead/Cancelled |
MERCK & CO., Inc. 1992-02-03 |